Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 14004377 | PEGYLATED APELIN AND USES THEREOF | Non-Final OA | GENZYME CORPORATION |
| 17754712 | COMPOSITIONS AND METHODS FOR TREATING LIBERIBACTER DISEASES AND OTHER BACTERIAL DISEASES | Final Rejection | The Regents of the University of California |
| 18762553 | SERINE PROTEINASE INHIBITORS: SERP-1 AND SERP-1 RCL-DERIVED PEPTIDES EFFECT ON MICROBIOME COMPOSITION AND USES THEREOF | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 18258462 | Therapeutic Peptide Formulations | Non-Final OA | Eli Lilly and Company |
| 18138118 | FERRITIN NANOCAGE FUSED WITH PD-L1-BINDING PEPTIDE 1 AND USE THEREOF AS ANTICANCER IMMUNOTHERAPY AGENT | Final Rejection | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17843418 | PD-1-DECORATED NANOCAGES AND USES THEREOF | Non-Final OA | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18101233 | MEANS AND METHODS FOR TREATING COPPER-RELATED DISEASES | Non-Final OA | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. |
| 17662312 | MODIFIED FOLLICLE-STIMULATING HORMONE AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of Colorado, a body corporate |
| 18131524 | COLLAGEN HYDROLYSATE AS AN ACTIVE SUBSTANCE FOR DELAYING AGEING | Non-Final OA | GELITA AG |
| 17271978 | USE OF A PDE11 OR PDE2 INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | UNIVERSITEIT VAN AMSTERDAM |
| 18038588 | COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR | Non-Final OA | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18742358 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | Non-Final OA | COSETTE PHARMACEUTICALS, INC. |
| 18028712 | MU-DIGUETOXIN-DC1A VARIANT POLYPEPTIDES FOR PEST CONTROL | Non-Final OA | Vestaron Corporation |
| 18639253 | PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEIN | Non-Final OA | ANPEP INC. |
| 18249055 | GLP-1/GIP DUAL AGONISTS | Final Rejection | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 18004125 | THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES II | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18518134 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND ITS PREPARATION METHODS AND APPLICATIONS | Non-Final OA | Seinda Pharmaceutical Guangzhou Corporation |
| 18258469 | PEPTIDES FOR PREVENTING OR TREATING HEART AND BLOOD VESSEL DISEASES | Non-Final OA | RD NÉPHROLOGIE |
| 15045068 | STABLE AQUEOUS PARENTERAL PHARMACEUTICAL COMPOSITIONS OF INSULINOTROPIC PEPTIDES | Final Rejection | SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION |
| 18009452 | COMPOSITION FOR PREVENTION, IMPROVEMENT OR TREATMENT OF ALLERGIC DISEASE OR ITCHING COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENT | Non-Final OA | CAREGEN CO, LTD. |
| 18037505 | ERYTHROPOIETIN VARIANTS AND USES THEREOF | Non-Final OA | Chulabhorn Foundation |
| 18018482 | CONJUGATED HEPCIDIN MIMETICS | Non-Final OA | Protagonist Therapeutics, Inc. |
| 18018412 | COSMETIC OR DERMATOLOGICAL PEPTIDE-BASED TREATMENT OF THE SKIN AND ITS INTEGUMENTS | Non-Final OA | Sederma |
| 18007513 | INSECT NEUROPEPTIDE ANALOGUES | Non-Final OA | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW |
| 17781907 | ANTIMICROBIAL PEPTIDES | Non-Final OA | SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE |
| 17743488 | COMPOSITIONS OF GROWTH FACTOR FOR THE TREATMENT OF EYE DISEASE | Non-Final OA | Claris Biotherapeutics, Inc. |
| 17765162 | METHODS OF TREATMENT FOR MODIFYING HEMODYNAMICS | Final Rejection | EBI ANTI SEPSIS B.V. |
| 17617043 | DEFERRED TREATMENT OF NERVE INJURIES | Final Rejection | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center |
| 17615857 | LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY | Non-Final OA | Medici Therapeutics, Inc. |
| 16476443 | NOVEL PROTEINS AND USE THEREOF | Non-Final OA | EVOLVERITAS KFT. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy